BTCC / BTCC Square / Global Cryptocurrency /

Anthropic’s Claude AI Accelerates Drug Research as Pharma Giants Adopt Chatbot Technology

Anthropic’s Claude AI Accelerates Drug Research as Pharma Giants Adopt Chatbot Technology

Author:

Global Cryptocurrency

Published:

2025-10-21 14:33:02

15

1

BTCCSquare news:

Anthropic is tailoring its Claude chatbot for life sciences, integrating it with lab software to streamline data analysis and documentation. Pharmaceutical leader Novo Nordisk reportedly reduced study paperwork from 10 weeks to 10 minutes using Claude, while Sanofi has deployed the tool for daily use across most operations.

The AI race intensifies as OpenAI, Mistral, and Alphabet's Google DeepMind enter the biomedical space. Alphabet's Gemma model recently identified a novel cancer therapy pathway, though no AI-discovered drugs have yet cleared regulatory hurdles. These developments signal a broader transformation in research methodologies across healthcare and adjacent sectors.

By:

AI Infrastructure Stocks: Nebius Group vs. CoreWeave Surge Amid Computing Demand Boom

|Square

Get the BTCC app to start your crypto journey

Download on the App Store GEI IT ON Google Play

Get started today Scan to join our 100M+ users

Risk warning: Digital asset trading is an emerging industry with bright prospects, but it also comes with huge risks as it is a new market. The risk is especially high in leveraged trading since leverage magnifies profits and amplifies risks at the same time. Please make sure you have a thorough understanding of the industry, the leveraged trading models, and the rules of trading before opening a position. Additionally, we strongly recommend that you identify your risk tolerance and only accept the risks you are willing to take. All trading involves risks, so you must be cautious when entering the market.

The world’s longest-running cryptocurrency exchange since 2011 © 2011 - 2025 BTCC.com. All rights reserved

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.